Gilead shows its belief in its partner’s cancer treatment with a $7.8 billion buyout
Arcellx’s stock is heading toward a record after the $7.8 billion deal to be acquired by Gilead.
📰 Original Source
Read full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.